

Client: ARUP Example Report Only 500 Chipeta Way Salt Lake City, UT 84108

Physician: TEST, TEST

UNITED STATES

**Patient: Patient, Example** 

DOB 1/10/1975 Sex: Female

**Patient Identifiers:** 55605 **Visit Number (FIN):** 55993

**Collection Date:** 12/20/2023 10:02

## Narcolepsy HLA-DQ Genotyping (HLA-DQB1\*06:02)

ARUP test code 3017170

HLA-DQB1, Allele 1 06:02

HLA-DQB1, Allele 2 06:02

## Narcolepsy HLA Interpretation

Positive for HLA-DQB1\*06:02, two copies. The HLA-DQB1\*06:02 allele, which is strongly associated with narcolepsy, was detected. Two copies of the HLA-DQB1\*06:02 allele double the risk for narcolepsy, compared to just one copy. This result is supportive of a clinical diagnosis of narcolepsy, but by itself does not establish a diagnosis. Medical screening and management of this individual should rely on clinical findings.

See Note

BACKGROUND INFORMATION: Narcolepsy Genotyping (HLA-DQB1\*06:02)

Characteristics: Narcolepsy is a chronic neurological sleep disorder that manifests in excessive daytime\_sleepiness\_and difficulty in maintaining wakefulness. Narcolepsy type 1 is associated with cataplexy (the sudden loss of muscle tone triggered by strong emotions). Additionally, disturbed nighttime sleep, sleep paralysis, and hypnagogic hallucinations (occurring in the period between sleep and wakefulness) are common.

Incidence: Varies, depending on ethnicity. It affects 0.02-0.05% of the populations in the US and Europe, it is most common in Japan (0.16-0.18%).

Inheritance: Multifactorial.

Cause: The HLA-DQB1\*06:02 allele is strongly associated with narcolepsy, but by itself is not causative. Homozygosity for DQB1\*06:02 allele doubles the risk, compared to heterozygous individuals.

Alleles Tested: HLA-DQB1 alleles.

Clinical Sensitivity: 85-95 percent depending on ethnicity. Greater than 98% of affected Caucasians with cataplexy have the HLA-DQB1\*06:02 allele.

Clinical Specificity: Less than 1 percent; 15-25 percent of unaffected Caucasians carry the HLA-DQB1\*06:02 allele.

Methodology: Polymerase Chain Reaction/Massively Parallel Sequencing, or Polymerase Chain Reaction/Sequence-Specific Oligonucleotide Probe Hybridization

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

Patient: Patient, Example



Analytical Sensitivity and Specificity: 99 percent.

Limitations: Rare diagnostic errors may occur due to primer site mutations. Other genetic and nongenetic factors that influence narcolepsy disease are not evaluated. In cases where an HLA allele cannot be resolved unambiguously, the allele assignment will be reported as the most common, based on allele frequencies from the common, intermediate, and well-documented alleles catalogue version 3.0.0 (Hurley CK et al, 2020).

This test was developed and its performance characteristics determined by the Histocompatibility & Immunogenetics laboratory at the University of Utah Health. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Histocompatibility & Immunogenetics laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

Performed at: Histocompatibility & Immunogenetics Laboratory, University of Utah Health, 417 Wakara Way, Suite 3220, Salt Lake City, UT 84108.

CLIA Number: 46D0679773

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

| VERIFIED/REPORTED DATES       |               |                        |                        |                        |
|-------------------------------|---------------|------------------------|------------------------|------------------------|
| Procedure                     | Accession     | Collected              | Received               | Verified/Reported      |
| HLA-DQB1, Allele 1            | 23-354-103968 | 12/20/2023 10:02:00 AM | 12/20/2023 10:52:20 AM | 12/20/2023 10:57:00 AM |
| HLA-DQB1, Allele 2            | 23-354-103968 | 12/20/2023 10:02:00 AM | 12/20/2023 10:52:20 AM | 12/20/2023 10:57:00 AM |
| Narcolepsy HLA Interpretation | 23-354-103968 | 12/20/2023 10:02:00 AM | 12/20/2023 10:52:20 AM | 12/20/2023 10:57:00 AM |

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical